AR034297A1 - Derivados quimicos y su aplicacion como agente antitelomerasa - Google Patents
Derivados quimicos y su aplicacion como agente antitelomerasaInfo
- Publication number
- AR034297A1 AR034297A1 ARP020101060A ARP020101060A AR034297A1 AR 034297 A1 AR034297 A1 AR 034297A1 AR P020101060 A ARP020101060 A AR P020101060A AR P020101060 A ARP020101060 A AR P020101060A AR 034297 A1 AR034297 A1 AR 034297A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- alkyl
- optionally substituted
- different
- group
- Prior art date
Links
- -1 C1-4 alkyl radical Chemical class 0.000 abstract 20
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 4
- 150000003254 radicals Chemical class 0.000 abstract 4
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical compound C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091081406 G-quadruplex Proteins 0.000 abstract 1
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthalene Natural products C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 abstract 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005237 alkyleneamino group Chemical group 0.000 abstract 1
- 239000012964 benzotriazole Substances 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0103916A FR2822468B1 (fr) | 2001-03-23 | 2001-03-23 | Derives chimiques et leur application comme agent anti-telomerase |
| FR0110370 | 2001-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034297A1 true AR034297A1 (es) | 2004-02-18 |
Family
ID=26212933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101060A AR034297A1 (es) | 2001-03-23 | 2002-03-22 | Derivados quimicos y su aplicacion como agente antitelomerasa |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1373252A1 (enExample) |
| JP (1) | JP2004524349A (enExample) |
| AR (1) | AR034297A1 (enExample) |
| AU (1) | AU2002251140B2 (enExample) |
| CA (1) | CA2442012A1 (enExample) |
| CO (1) | CO5380035A1 (enExample) |
| IL (2) | IL158056A0 (enExample) |
| MX (1) | MXPA03008269A (enExample) |
| MY (1) | MY130957A (enExample) |
| PE (1) | PE20020959A1 (enExample) |
| WO (1) | WO2002076975A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002314252A1 (en) | 2001-05-28 | 2002-12-09 | Aventis Pharma S.A. | Chemical derivatives and the use thereof as an anti-telomerase agent |
| US7173032B2 (en) * | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| WO2004001018A2 (en) * | 2002-06-25 | 2003-12-31 | The Center For Blood Research, Inc. | Vacuolins |
| FR2850970B1 (fr) * | 2003-02-07 | 2006-07-07 | Aventis Pharma Sa | Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| CA2531327A1 (en) | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | Compounds and therapeutical use thereof |
| CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| JP2008540585A (ja) * | 2005-05-19 | 2008-11-20 | プロメティック・バイオサイエンスィズ・インコーポレーテッド | 転移性メラノーマ及び他の癌を治療するための化合物、そのような化合物を含有する組成物、および治療方法 |
| JP2009545592A (ja) * | 2006-07-31 | 2009-12-24 | プリーシス・ファーマシューティカルズ・インコーポレイテッド | コード化小分子ライブラリーからのオーロラキナーゼ阻害剤 |
| US8415340B2 (en) * | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| FR2948686B1 (fr) * | 2009-07-30 | 2011-08-19 | Biomerieux Sa | Nouveaux substrats de peptidase |
| US20210024455A1 (en) * | 2018-03-20 | 2021-01-28 | Hiroshima University | Compound which inhibits telomere-binding protein, and telomere-binding protein inhibitor containing same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206768D0 (en) * | 1992-03-27 | 1992-05-13 | Jarman Michael | New compounds for use in the treatment of cancer |
| JPH1160573A (ja) * | 1997-08-22 | 1999-03-02 | Nippon Kayaku Co Ltd | トリアジン誘導体及びテロメラーゼ阻害剤 |
| US6262053B1 (en) * | 1999-06-23 | 2001-07-17 | Parker Hughes Institute | Melamine derivatives as potent anti-cancer agents |
| IL149402A0 (en) * | 1999-11-29 | 2002-11-10 | Aventis Pharma Sa | Arylamine derivatives and their use as anti-telomerase agent |
| ATE511858T1 (de) * | 2002-02-05 | 2011-06-15 | Astellas Pharma Inc | 2,4,6-triamino-1,3,5-triazin-derivat |
-
2002
- 2002-03-21 CO CO02025874A patent/CO5380035A1/es not_active Application Discontinuation
- 2002-03-22 MY MYPI20021036A patent/MY130957A/en unknown
- 2002-03-22 EP EP02720068A patent/EP1373252A1/fr not_active Withdrawn
- 2002-03-22 PE PE2002000227A patent/PE20020959A1/es not_active Application Discontinuation
- 2002-03-22 MX MXPA03008269A patent/MXPA03008269A/es not_active Application Discontinuation
- 2002-03-22 JP JP2002576233A patent/JP2004524349A/ja not_active Ceased
- 2002-03-22 CA CA002442012A patent/CA2442012A1/fr not_active Abandoned
- 2002-03-22 AU AU2002251140A patent/AU2002251140B2/en not_active Ceased
- 2002-03-22 IL IL15805602A patent/IL158056A0/xx unknown
- 2002-03-22 WO PCT/FR2002/001005 patent/WO2002076975A1/fr not_active Ceased
- 2002-03-22 AR ARP020101060A patent/AR034297A1/es unknown
-
2003
- 2003-09-22 IL IL158056A patent/IL158056A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL158056A0 (en) | 2004-03-28 |
| EP1373252A1 (fr) | 2004-01-02 |
| CA2442012A1 (fr) | 2002-10-03 |
| MY130957A (en) | 2007-07-31 |
| IL158056A (en) | 2010-02-17 |
| JP2004524349A (ja) | 2004-08-12 |
| CO5380035A1 (es) | 2004-03-31 |
| AU2002251140B2 (en) | 2007-03-15 |
| MXPA03008269A (es) | 2004-10-15 |
| WO2002076975A1 (fr) | 2002-10-03 |
| PE20020959A1 (es) | 2002-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20260502A1 (es) | Fluoroalquil-oxadiazoles y usos de los mismos | |
| CO5251431A1 (es) | Derivados quimicos y su aplicacion como agente antitelomerasa | |
| CO4650042A1 (es) | Derivados de 6-fenilpiridil-2-amina | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR126108A1 (es) | Tratamientos para la degradación del braf mutante | |
| AR059085A1 (es) | Derivados azufrados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de quinasas | |
| AR059086A1 (es) | Derivados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de cinasas | |
| AR097008A1 (es) | Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| FR2809396B1 (fr) | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation | |
| AR031716A1 (es) | Derivados de 1-aza y 1,3- diazabicicloetanos y analogos, un procedimiento para su preparacion, y composicion farmaceutica y medicamentos como antibacterianos | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| PE20040411A1 (es) | Compuestos de aril cetona pirrolo triazina | |
| AR098337A1 (es) | Triazolopirazina | |
| CO4520230A1 (es) | Derivados de [3-(4-fenilpiperacin-1-il) propilamino, tio y oxilo]-piridina, pirimidina y benceno como antagonistas de alfa 1- adrenoceptores | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO5380035A1 (es) | Derivados quimicos y su aplicacion como agente antitelomerasa | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR035317A1 (es) | Derivados de purina, su procedimiento de preparacion, medicamentos, composiciones farmaceuticas y utilizacion de compuestos para la preparacion de medicamentos | |
| AR050963A1 (es) | Derivados bis-azaindolicos, su utilizacion farmaceutica como inhibidores de cinasas y su uso en la fabricacion de medicamentos para el tratamiento de los canceres. | |
| JP2004524349A5 (enExample) | ||
| AR018979A1 (es) | 2-aminopiridinas que contienen sustituyentes de tipo anillo condensado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |